Skip to main content
Top
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules

Authors: Sara Tomei, Chiara Mazzanti, Ivo Marchetti, Leonardo Rossi, Katia Zavaglia, Francesca Lessi, Alessandro Apollo, Paolo Aretini, Giancarlo Di Coscio, Generoso Bevilacqua

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

A large amount of information has been collected on the molecular tumorigenesis of thyroid cancer. A low expression of c-KIT gene has been reported during the transformation of normal thyroid epithelium to papillary carcinoma suggesting a possible role of the gene in the differentiation of thyroid tissue rather than in the proliferation. The initial presentation of thyroid carcinoma is through a nodule and the best way nowadays to evaluate it is by fine-needle aspiration (FNA). However many thyroid FNAs are not definitively benign or malignant, yielding an indeterminate or suspicious diagnosis which ranges from 10 to 25% of FNAs. BRAF mutational analysis is commonly used to assess the malignancy of thyroid nodules but unfortunately it still leaves indeterminate diagnoses. The development of molecular initial diagnostic tests for evaluating a thyroid nodule is needed in order to define optimal surgical approach for patients with uncertain diagnosis pre- and intra-operatively.

Methods

In this study we extracted RNA from 82 FNA smears, 46 malignant and 36 benign at the histology, in order to evaluate by quantitative Real Time PCR the expression levels of c-KIT gene.

Results

We have found a highly preferential decrease rather than increase in transcript of c-KIT in malignant thyroid lesions compared to the benign ones. To explore the diagnostic utility of c-KIT expression in thyroid nodules, its expression values were divided in four arbitrarily defined classes, with class I characterized by the complete silencing of the gene. Class I and IV represented the two most informative groups, with 100% of the samples found malignant or benign respectively. The molecular analysis was proven by ROC (receiver operating characteristic) analysis to be highly specific and sensitive improving the cytological diagnostic accuracy of 15%.

Conclusion

We propose the use of BRAF test (after uncertain cytological diagnosis) to assess the malignancy of thyroid nodules at first, then the use of the c-KIT expression to ultimately assess the diagnosis of the nodules that otherwise would remain suspicious. The c-KIT expression-based classification is highly accurate and may provide a tool to overcome the difficulties in today's preoperative diagnosis of thyroid suspicious malignancies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Hodgson NC, Button J, Solorzano CC: Thyroid cancer: is the incidence still increasing?. Ann Surg Oncol. 2004, 11: 1093-1097. 10.1245/ASO.2004.03.066.CrossRefPubMed Hodgson NC, Button J, Solorzano CC: Thyroid cancer: is the incidence still increasing?. Ann Surg Oncol. 2004, 11: 1093-1097. 10.1245/ASO.2004.03.066.CrossRefPubMed
2.
go back to reference Miccoli P, Minuto MN, Galleri D, D'Agostino J, Basolo F, Antonangeli L, Aghini-Lombardi F, Berti P: Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg. 2006, 76: 123-126. 10.1111/j.1445-2197.2006.03667.x.CrossRefPubMed Miccoli P, Minuto MN, Galleri D, D'Agostino J, Basolo F, Antonangeli L, Aghini-Lombardi F, Berti P: Incidental thyroid carcinoma in a large series of consecutive patients operated on for benign thyroid disease. ANZ J Surg. 2006, 76: 123-126. 10.1111/j.1445-2197.2006.03667.x.CrossRefPubMed
3.
go back to reference Udelsman R, Chen H: The current management of thyroid cancer. Adv Surg. 1999, 33: 1-27.PubMed Udelsman R, Chen H: The current management of thyroid cancer. Adv Surg. 1999, 33: 1-27.PubMed
4.
go back to reference Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med. 1993, 328: 553-559. 10.1056/NEJM199302253280807.CrossRefPubMed Mazzaferri EL: Management of a solitary thyroid nodule. N Engl J Med. 1993, 328: 553-559. 10.1056/NEJM199302253280807.CrossRefPubMed
5.
go back to reference Hegedus L: Clinical practice. The thyroid nodule. N Engl J Med. 2004, 351: 1764-1771. 10.1056/NEJMcp031436.CrossRefPubMed Hegedus L: Clinical practice. The thyroid nodule. N Engl J Med. 2004, 351: 1764-1771. 10.1056/NEJMcp031436.CrossRefPubMed
7.
go back to reference de Silva CM, Reid R: Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res. 2003, 9: 13-19. 10.1007/BF03033708.CrossRefPubMed de Silva CM, Reid R: Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res. 2003, 9: 13-19. 10.1007/BF03033708.CrossRefPubMed
8.
go back to reference Ronnstrand L: Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004, 61: 2535-2548. 10.1007/s00018-004-4189-6.CrossRefPubMed Ronnstrand L: Signal transduction via the stem cell factor receptor/c-Kit. Cell Mol Life Sci. 2004, 61: 2535-2548. 10.1007/s00018-004-4189-6.CrossRefPubMed
9.
go back to reference D'Amato G, Steinert DM, McAuliffe JC, Trent JC: Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005, 12: 44-56.PubMed D'Amato G, Steinert DM, McAuliffe JC, Trent JC: Update on the biology and therapy of gastrointestinal stromal tumors. Cancer Control. 2005, 12: 44-56.PubMed
10.
go back to reference Miettinen M, Makhlouf H, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006, 30: 477-489. 10.1097/00000478-200604000-00008.CrossRefPubMed Miettinen M, Makhlouf H, Sobin LH, Lasota J: Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006, 30: 477-489. 10.1097/00000478-200604000-00008.CrossRefPubMed
11.
go back to reference McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J: Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005, 65: 8085-8089. 10.1158/0008-5472.CAN-05-0471.CrossRefPubMed McIntyre A, Summersgill B, Grygalewicz B, Gillis AJ, Stoop J, van Gurp RJ, Dennis N, Fisher C, Huddart R, Cooper C, Clark J, Oosterhuis JW, Looijenga LH, Shipley J: Amplification and overexpression of the KIT gene is associated with progression in the seminoma subtype of testicular germ cell tumors of adolescents and adults. Cancer Res. 2005, 65: 8085-8089. 10.1158/0008-5472.CAN-05-0471.CrossRefPubMed
12.
go back to reference All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O: c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?. Invest Ophthalmol Vis Sci. 2004, 45: 2075-2082. 10.1167/iovs.03-1196.CrossRefPubMed All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O: c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target?. Invest Ophthalmol Vis Sci. 2004, 45: 2075-2082. 10.1167/iovs.03-1196.CrossRefPubMed
13.
go back to reference Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M: Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996, 13: 2339-2347.PubMed Huang S, Luca M, Gutman M, McConkey DJ, Langley KE, Lyman SD, Bar-Eli M: Enforced c-KIT expression renders highly metastatic human melanoma cells susceptible to stem cell factor-induced apoptosis and inhibits their tumorigenic and metastatic potential. Oncogene. 1996, 13: 2339-2347.PubMed
14.
go back to reference Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS, Cho EY, Gong G, Ahn SH: The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis. 2003, 20: 593-597. 10.1023/A:1027323210736.CrossRefPubMed Ko CD, Kim JS, Ko BG, Son BH, Kang HJ, Yoon HS, Cho EY, Gong G, Ahn SH: The meaning of the c-kit proto-oncogene product in malignant transformation in human mammary epithelium. Clin Exp Metastasis. 2003, 20: 593-597. 10.1023/A:1027323210736.CrossRefPubMed
15.
go back to reference Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S: A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer. 2006, 94: 1874-1878. 10.1038/sj.bjc.6603183.CrossRefPubMedPubMedCentral Tsutsui S, Yasuda K, Suzuki K, Takeuchi H, Nishizaki T, Higashi H, Era S: A loss of c-kit expression is associated with an advanced stage and poor prognosis in breast cancer. Br J Cancer. 2006, 94: 1874-1878. 10.1038/sj.bjc.6603183.CrossRefPubMedPubMedCentral
16.
go back to reference Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R: c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004, 83: 33-42. 10.1023/B:BREA.0000010694.35023.9e.CrossRefPubMed Ulivi P, Zoli W, Medri L, Amadori D, Saragoni L, Barbanti F, Calistri D, Silvestrini R: c-kit and SCF expression in normal and tumor breast tissue. Breast Cancer Res Treat. 2004, 83: 33-42. 10.1023/B:BREA.0000010694.35023.9e.CrossRefPubMed
17.
go back to reference Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G: Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res. 1995, 55: 1787-1791.PubMed Natali PG, Berlingieri MT, Nicotra MR, Fusco A, Santoro E, Bigotti A, Vecchio G: Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res. 1995, 55: 1787-1791.PubMed
18.
go back to reference Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004, 64: 2898-2903. 10.1158/0008-5472.CAN-03-3811.CrossRefPubMed Mazzanti C, Zeiger MA, Costouros NG, Umbricht C, Westra WH, Smith D, Somervell H, Bevilacqua G, Alexander HR, Libutti SK: Using gene expression profiling to differentiate benign versus malignant thyroid tumors. Cancer Res. 2004, 64: 2898-2903. 10.1158/0008-5472.CAN-03-3811.CrossRefPubMed
19.
go back to reference Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008, 14: 3327-3337. 10.1158/1078-0432.CCR-07-4495.CrossRefPubMedPubMedCentral Prasad NB, Somervell H, Tufano RP, Dackiw AP, Marohn MR, Califano JA, Wang Y, Westra WH, Clark DP, Umbricht CB, Libutti SK, Zeiger MA: Identification of genes differentially expressed in benign versus malignant thyroid tumors. Clin Cancer Res. 2008, 14: 3327-3337. 10.1158/1078-0432.CCR-07-4495.CrossRefPubMedPubMedCentral
20.
go back to reference Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK: A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005, 138: 1050-1056. 10.1016/j.surg.2005.09.010. discussion 1056-1057CrossRefPubMed Rosen J, He M, Umbricht C, Alexander HR, Dackiw AP, Zeiger MA, Libutti SK: A six-gene model for differentiating benign from malignant thyroid tumors on the basis of gene expression. Surgery. 2005, 138: 1050-1056. 10.1016/j.surg.2005.09.010. discussion 1056-1057CrossRefPubMed
21.
go back to reference He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005, 102: 19075-19080. 10.1073/pnas.0509603102.CrossRefPubMedPubMedCentral He H, Jazdzewski K, Li W, Liyanarachchi S, Nagy R, Volinia S, Calin GA, Liu CG, Franssila K, Suster S, Kloos RT, Croce CM, de la Chapelle A: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA. 2005, 102: 19075-19080. 10.1073/pnas.0509603102.CrossRefPubMedPubMedCentral
22.
go back to reference Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A: Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 2011, 21: 111-118. 10.1089/thy.2010.0356.CrossRefPubMed Mazeh H, Mizrahi I, Halle D, Ilyayev N, Stojadinovic A, Trink B, Mitrani-Rosenbaum S, Roistacher M, Ariel I, Eid A, Freund HR, Nissan A: Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid. 2011, 21: 111-118. 10.1089/thy.2010.0356.CrossRefPubMed
23.
go back to reference Hamberger B, Gharib H, Melton LJ, Goellner JR, Zinsmeister AR: Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med. 1982, 73: 381-384. 10.1016/0002-9343(82)90731-8.CrossRefPubMed Hamberger B, Gharib H, Melton LJ, Goellner JR, Zinsmeister AR: Fine-needle aspiration biopsy of thyroid nodules. Impact on thyroid practice and cost of care. Am J Med. 1982, 73: 381-384. 10.1016/0002-9343(82)90731-8.CrossRefPubMed
24.
go back to reference Suen KC: How does one separate cellular follicular lesions of the thyroid by fine-needle aspiration biopsy?. Diagn Cytopathol. 1988, 4: 78-81. 10.1002/dc.2840040119.CrossRefPubMed Suen KC: How does one separate cellular follicular lesions of the thyroid by fine-needle aspiration biopsy?. Diagn Cytopathol. 1988, 4: 78-81. 10.1002/dc.2840040119.CrossRefPubMed
25.
go back to reference Caraway NP, Sneige N, Samaan NA: Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol. 1993, 9: 345-350. 10.1002/dc.2840090320.CrossRefPubMed Caraway NP, Sneige N, Samaan NA: Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol. 1993, 9: 345-350. 10.1002/dc.2840090320.CrossRefPubMed
26.
go back to reference Goellner JR: Problems and pitfalls in thyroid cytology. Monogr Pathol. 1997, 75-93. Goellner JR: Problems and pitfalls in thyroid cytology. Monogr Pathol. 1997, 75-93.
27.
go back to reference Goellner JR, Gharib H, Grant CS, Johnson DA: Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987, 31: 587-590.PubMed Goellner JR, Gharib H, Grant CS, Johnson DA: Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987, 31: 587-590.PubMed
28.
go back to reference Ravetto C, Colombo L, Dottorini ME: Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer. 2000, 90: 357-363. 10.1002/1097-0142(20001225)90:6<357::AID-CNCR6>3.0.CO;2-4.CrossRefPubMed Ravetto C, Colombo L, Dottorini ME: Usefulness of fine-needle aspiration in the diagnosis of thyroid carcinoma: a retrospective study in 37,895 patients. Cancer. 2000, 90: 357-363. 10.1002/1097-0142(20001225)90:6<357::AID-CNCR6>3.0.CO;2-4.CrossRefPubMed
29.
go back to reference Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G: A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009, 19: 837-842. 10.1089/thy.2009.0074.CrossRefPubMed Marchetti I, Lessi F, Mazzanti CM, Bertacca G, Elisei R, Coscio GD, Pinchera A, Bevilacqua G: A morpho-molecular diagnosis of papillary thyroid carcinoma: BRAF V600E detection as an important tool in preoperative evaluation of fine-needle aspirates. Thyroid. 2009, 19: 837-842. 10.1089/thy.2009.0074.CrossRefPubMed
30.
go back to reference Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007, 28: 742-762. 10.1210/er.2007-0007.CrossRefPubMed Xing M: BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev. 2007, 28: 742-762. 10.1210/er.2007-0007.CrossRefPubMed
31.
go back to reference Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63: 1454-1457.PubMed Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA: High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003, 63: 1454-1457.PubMed
32.
go back to reference Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005, 115: 1068-1081.CrossRefPubMedPubMedCentral Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005, 115: 1068-1081.CrossRefPubMedPubMedCentral
33.
go back to reference Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990, 63: 213-224. 10.1016/0092-8674(90)90302-U.CrossRefPubMed Zsebo KM, Williams DA, Geissler EN, Broudy VC, Martin FH, Atkins HL, Hsu RY, Birkett NC, Okino KH, Murdock DC: Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell. 1990, 63: 213-224. 10.1016/0092-8674(90)90302-U.CrossRefPubMed
34.
go back to reference Jin L, Lloyd RV, Nassar A, Lappinga PJ, Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR, Oliveira AM, Zhang J: HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol. 2011, 20: 71-80. 10.1097/PDM.0b013e3181ed784d.CrossRefPubMed Jin L, Lloyd RV, Nassar A, Lappinga PJ, Sebo TJ, Swartz K, Seys AR, Erickson-Johnson MR, Roth CW, Evers BR, Oliveira AM, Zhang J: HMGA2 expression analysis in cytological and paraffin-embedded tissue specimens of thyroid tumors by relative quantitative RT-PCR. Diagn Mol Pathol. 2011, 20: 71-80. 10.1097/PDM.0b013e3181ed784d.CrossRefPubMed
Metadata
Title
c-KIT receptor expression is strictly associated with the biological behaviour of thyroid nodules
Authors
Sara Tomei
Chiara Mazzanti
Ivo Marchetti
Leonardo Rossi
Katia Zavaglia
Francesca Lessi
Alessandro Apollo
Paolo Aretini
Giancarlo Di Coscio
Generoso Bevilacqua
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-7

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.